MORE►
ophthalmology
Marketing image for one of Eyevance Pharmaceuticals' products, Flarex. [eyevance.com]
Fort Worth Ophthalmic Biotech Eyevance Exits to Japanese Firm for $225M
by Alex Edwards | Sep 17, 2020
Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
by Lance Murray |
Jan 8, 2020
The startup plans to use the funding to continue developing its technology and to position it as an innovator in ophthalmology. Eyevensys’ tech is a gene therapy platform to deliver ocular drugs via an electrotransfection system to the ciliary muscle of the eye.
MORE►
by Lance Murray |
May 10, 2019
You’ll also find out why the Association for Research in Vision and Ophthalmology has honored a professor at the UNT Health Science Center in Fort Worth in this roundup of research and development activity in North Texas.
MORE►
